Compare Mesoblast Limited (MESO) vs Trane Technologies plc (TT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Trane Technologies plc — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Trane Technologies plc trades at $471.29 (market cap $105.17B). The key difference: Trane Technologies plc is far larger — about 57.5× Mesoblast Limited's market cap, and Trane Technologies plc pays a 0.88% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TT | |
|---|---|---|
Market Cap | $1.83B | $105.17B |
Volume | 259,445 | 1,040,183 |
Sector | Health | Industrials |
52-Week High | $20.96 | $503.46 |
52-Week Low | $13.19 | $376.43 |
Typical Hold Time | 15 Days | — |
Enterprise Value | $1.91B | $108.47B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Trane Technologies plc
Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.
Read more on TT →
